Serum LincLNMAT1 Correlated With Phosphorylated α-synuclein As Important Biomarkers Of Parkinson’s Disease: A Cross-sectional Study | 106501
Journal of Neurology & Neurophysiology
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Early diagnosis of Parkinson???s Disease (PD) is an important issue to improve the prognosis. Long noncoding
RNA (lncRNA) has been reported to have a function in the pathogenesis of PD. In this study it is reported
that a long noncoding RNA, lincLNMAT1 in serum involved in the diagnosis of PD and correlated with
serum phosphorylated ?-synuclein (PS-129 ?-Syn) in PD. In this study, it is detected serum lincLNMAT1
expression in 218 PD patients and 175 healthy volunteers by using the quantitative Real-Time Polymerase
Chain Reaction (qRT-PCR) method. Serum PS-129 ?-syn concentrations were measured by ELISA assay.
Receivers Operating Characteristic (ROC) curves were applied to map the diagnostic accuracy of PD patients
compared to healthy subjects. Several scales were used to rate the severity of PD patients. The expression level
of serum lincLNMAT1 (0.196±0.018) was significantly higher in PD patients compared with that of healthy
controls (0.042±0.005). Serum PS-129 ?-syn level was also found to be higher in PD patients (36.18±2.62
ng/?L) than healthy controls (30.05±2.11 ng/?L). Clinical data indicated that serum lincLNMAT1 was
positively correlated with H and Y stage and the unified Parkinson's disease rating scale III (UPDRS III)
score. Moreover, there was a significant positive correlation between serum lincLNMAT1 levels and serum
PS-129 ?-syn according to Spearman???s rank correlation analysis. The ROC curve for lincLNMAT1 (AUC
0.795) showed potential diagnostic value in discriminating PD from healthy subjects. This study, for the first
time, demonstrated that serum lincLNMAT1 might serve as a potent serum protein marker for the diagnosis
Jing Zou has completed her PhD from Sun Yat-sen University in 2017 and Postdoctoral studies at Mayo Clinic, USA. Currently, she is working as a Clinical Research Scientist in Department of Neurology and Stroke Center, Clinical Neuroscience Institute of Jinan University, Guangzhou, China. She has published 11 journal papers.